Home

Stephane Bancel

CIK 1443340 · Chief Executive Officer · last filed 2026-08-07

Stephane Bancel is a Chief Executive Officer who has filed 325 SEC Form 4 insider transactions across 5 companies since 2008. The most recent filing, for MRNA, was dated Aug 7, 2026. Across all open-market trades the lifetime net is −$1.25B, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.88B across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$1.88B

Companies

5

Total Filings

325

Lifetime Open-Market Net

-$1.25B

Filer Profile

Reported Address
325 BINNEY STREET
CAMBRIDGE, MA 02142
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
MRNA Chief Executive Officer 12,939,715 $143.97 $1.86B -$1.25B 286 2026-08-07
GENB Director 1,184,989 $15.72 $18.63M $0 1 2026-03-02
Syros Pharmaceuticals, Inc. (SYRS) Delisted Director 4,798 $0.00 $2 $0 2 2016-09-19
BG Medicine, Inc. (BGMD) Delisted Executive Chairman 30,792 — — $226.1K 11 2013-11-04
Targanta Therapeutics Corp. (TARG) Delisted Director — — — $0 1 2008-08-26

Recent Filings

325 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-08-07 MRNA Mixed +252,469 -$14.32M EDGAR
2026-08-07 MRNA Mixed +252,469 -$14.32M EDGAR
2026-08-05 MRNA Notice (144) −499,246 -$28.96M EDGAR
2026-03-03 MRNA Grant (A) — $0 EDGAR
2026-03-02 GENB Mixed +724,160 $0 EDGAR
2026-02-13 MRNA Mixed +5,821 -$228.8K EDGAR
2025-12-15 MRNA Exer (M) +688,073 $7.50M EDGAR
2025-03-04 MRNA Buy (P) +160,314 $5.00M EDGAR
2025-03-03 MRNA Grant (A) — $0 EDGAR
2025-02-14 MRNA Mixed +6,833 -$198.0K EDGAR
Showing 1–10 of 325
Page 1 of 33
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.